Abstract: The present application provides a composition for inducing chondrogenesis comprising an Wnt antagonist and a pharmaceutically acceptable carrier. The present application also provides a method for inducing chondrogenesis comprising administering an Wnt antagonist and a pharmaceutically acceptable carrier to a subject. The present application further provides a method for treating a cartilage-related disease comprising administering a therapeutically effective amount of an Wnt antagonist and a pharmaceutically acceptable carrier to a subject.

Abstract: A focused ultrasound device and method for dermatological treatment. The focused ultrasound device includes a focused ultrasound applicator, an automatic motion mechanism, a driver, a computer, a software operation interface. In addition, the focused ultrasound method for dermatological treatment utilizes the same focused ultrasound applicator, to achieve coaxial deep layer and shallow layer ablation treatment of the skin.

Abstract: A target particle transferring device is disclosed, which comprises: (a) a substrate with a thickness of T and a width of W, having top and bottom portions, the top portion having a top surface and the bottom portion having a bottom surface; (b) a notch structure formed in the bottom portion of the substrate, comprising: a groove with a width of W1, located at a distance oft below the top surface of the substrate, wherein the groove is formed in the bottom portion from the bottom surface extending toward the top portion; and (c) a target substrate portion with a width of W2 and a thickness of T, located in the top and bottom portions of the substrate and being surrounded by the groove. Methods of transferring a target particle from one device to another is also disclosed.

Abstract: An electronic device and a method for selecting a feature of an electrocardiogram (ECG) are provided. The method includes: obtaining the ECG; performing a first pre-processing on the ECG to generate a first ECG; marking multiple extreme points corresponding to at least one type of wave on the first ECG; calculating a first feature value corresponding to a first feature according to the multiple extreme points of the at least one type of wave, generating a first performance index corresponding to a machine learning model according to the first feature value, and determining whether to select the first feature according to the first performance index; and outputting the first feature in response to selecting the first feature.

Abstract: An electronic device and a method for predicting a blockage of a coronary artery are provided. The method includes: obtaining multiple pieces of electrocardiogram (ECG) data respectively corresponding to a coronary artery set; generating multiple first probabilities corresponding to the multiple pieces of electrocardiogram data respectively according to the multiple pieces of electrocardiogram data and a first phase model, generating a first determined result according to the multiple first probabilities, and selecting a first data subset corresponding to a first probability subset from the multiple pieces of electrocardiogram data in response to each one in the first data subset of the multiple first probabilities being greater than a first threshold; generating multiple second probabilities corresponding to the first data subset according to the first data subset and a second phase model, and generating a second determined result according to the multiple second probabilities.

Abstract: An electronic device and a method for screening features for predicting a physiological state are provided. The method includes: obtaining multiple physiological data corresponding to multiple features; generating multiple first subsets of the multiple features according to the multiple physiological data based on a first model, wherein the multiple first subsets respectively correspond to the multiple physiological data; selecting a first feature from the multiple features according to the multiple first subsets, calculating a first relation index of the first feature and a second feature corresponding to the multiple features, and selecting the second feature as an accompanied feature of the first feature according to the first relation index; and outputting the first feature and the accompanied feature.

Abstract: The present invention provides novel substituted benzimidazole derivatives of formula (I) used as DAAO inhibitors and for treatment and/or prevention of neurological disorders.

Abstract: A method for identifying an AhR-phospho-ROR?t protein complex inhibitor, comprising: (a) providing a cell culture, in which cells in the culture express AhR protein and phospho-ROR?t protein; (b) incubating the cell culture in the presence of a test agent; (c) assaying the level of the AhR-phospho-ROR?t protein complex in the presence of the test agent; (d) comparing the level of the AhR-phospho-ROR?t protein complex in the presence of the test agent with a control; and (e) identifying the test agent as the inhibitor of the AhR-phospho-ROR?t protein complex when the comparing step indicates that there is a reduction in the level of the AhR-phospho-ROR?t protein complex in the presence of the test agent as compared with the control. A method for identifying a GLK?IQGAP1 protein complex inhibitor is also disclosed. Use of identified inhibitors in the manufacture of a medicament for treating a disease is also disclosed.

Abstract: Thiazole compounds of Formula (I) shown below and pharmaceutical compositions containing one of such compounds: wherein R1 and R2 are defined in the specification. Also disclosed are methods of inhibiting a tyrosine kinase and treating cancer associated with a tyrosine kinase with one of the thiazole compounds.

Abstract: The present application provides a method for genotyping M. tuberculosis, comprising obtaining amplifying and obtaining a first DNA fragment from a DNA sample by using one or more primer sets selected from the group consisting of primer sets 1 to 25 (SEQ ID Nos. 1 to 50); amplifying and obtaining a second DNA fragment from the obtained first DNA fragment by using one or more extension primers selected from the group consisting of SEQ ID Nos. 51 to 75; and detecting the second DNA fragment by using mass spectrometry, particularly by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS).

Abstract: Provided is a pharmaceutical composition, including an antigen fusion protein which includes an antigen and an antagonist of an Fc gamma receptor. Also provided is a method of enhancing immunogenicity of an antigen, including conjugating the antigen with an antagonist of an Fc gamma receptor to form an antigen fusion protein. Also provided is a method of enhancing an immune response to an antigen in a subject, including administering to the subject an effective amount of an antigen fusion protein which includes an antigen and an antagonist of an Fc gamma receptor. The present invention may be applied in the development of potent vaccines based on targeting vaccine antigens to antigen-presenting cells via binding to Fc gamma receptors.

Abstract: The present invention relates to a method for decreasing the psychotomimetic side effects and enhancing the antidepressant-like effects of ketamine by the combination of ketamine with a methylglycine derivative. The present invention also relates to a method for depression treatment comprising administrating ketamine combined with a methylglycine derivative. The present invention further provides a method for preventing or treating addictive disorders of ketamine by administrating a methylglycine derivative.

Abstract: The invention provides a nanoemulsion adjuvant and a preparation method thereof, which are composed of the following components: a continuous aqueous phase containing H2O molecules, an oil phase material containing fats and oils, and an emulsion system for stabilizing the interface between the continuous aqueous phase and the oil phase, and the emulsion system is an emulsifier mixture. The adjuvant is characterized in that the emulsion system does not contain an ionic emulsifier and the particle size of the emulsion is between 20 and 200 nanometers. The use of the nanoemulsion adjuvant can prevent toxicity and possible harm of ionic emulsifiers to human cells, and provide a vaccine preparation capable of eliciting a high degree of immune response.

Abstract: A method of producing induced exosomes, the method comprising: contacting an isolated population of stem cells with an amount of a prostaglandin E receptor 4 (EP4) antagonist effective for inducing release of exosomes, whereby induced exosomes are released from the stem cells, and isolating the induced exosomes.

Abstract: An isolated antibody, comprising a light-chain CDR1 (L-CDR1) having the sequence of SEQ ID NO: 1, SEQ ID NO: 7, or SEQ ID NO: 14; a light-chain CDR2 (L-CDR2) having the sequence of SEQ ID NO: 2 or SEQ ID NO: 15; a light-chain CDR3 (L-CDR3) having the sequence of SEQ ID NO: 3, SEQ ID NO: 8, SEQ ID NO: 21, or SEQ ID NO: 24; a heavy-chain CDR1 (H-CDR1) having the sequence of SEQ ID NO: 4, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 16, or SEQ ID NO: 25; a heavy-chain CDR2 (H-CDR2) having the sequence of SEQ ID NO: 5, SEQ ID NO: 12, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 22, or SEQ ID NO: 26; and a heavy-chain CDR3 (H-CDR3) having the sequence of SEQ ID NO: 6, SEQ ID NO: 10, SEQ ID NO: 13, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 23, or SEQ ID NO: 27, wherein the antibody specifically binds to A?1-42 or an N-terminal modified form thereof.

Abstract: An isolated antibody, comprising: heavy chain complementary determining regions CDR1, CDR2, and CDR3 of a heavy chain variable region sequence selected from SEQ ID NOs: 2, 6, 10, and 14; and light chain complementary determining regions CDR1, CDR2, and CDR3 of a light chain variable region sequence selected from SEQ ID NOs: 4, 8, 12, and 16; wherein the antibody binds specifically to a RSPO3 protein.

Abstract: Described herein are an immunogenic peptide containing the sequence of CLDSLGQWN (SEQ ID NO:2) and a method of using the peptide for treating cancer.

Abstract: The present invention relates to microbiota compositions and their preparation methods and uses. Particularly, the present invention provides microbiota compositions collected from a dual-specificity phosphatase 6 (dusp6) deficient mammal, which is effective in altering a relative abundance of gut microbiota and also useful in reducing body weight, fat mass, and/or size of adipocytes and increasing oxygen consumption and/or energy expenditure and thus can be used to treat or prevent obesity or its associated disorders or conditions in a subject in need.

Abstract: A hydrodynamic shuttling chip device comprising an array of single-cell trapping units is disclosed. Each unit comprises: (a) an incoming channel with a cell capture site; (b) a cell culture chamber located posterior to the cell capture site, having a receiving site spaced apart from the cell capture site at a distance of g; (c) a trapping channel located between the cell capture site and the receiving site; (d) a chamber channel located posterior to and in fluidic connection with the cell culture chamber; and (e) a by-pass channel, located lateral to the incoming channel, chamber and chamber channel and having a first end and a second end opposite to the first end, the first end branching out from the incoming channel immediately prior to the cell capture site and the second end joining the chamber channel. A method of capturing single cells of more than one type is also disclosed.

Abstract: The invention utilizes virtual screening strategy to seek for current market drugs as anti-schizophrenia therapy drug repurposing. Drug repurposing strategy finds new uses other than the original medical indications of existing drugs. Finding new indications for such drugs will benefit patients who are in needs for a potential new therapy sooner since known drugs are usually with acceptable safety and pharmacokinetic profiles. In this study, repurposing marketed drugs for DAAO inhibitor as new schizophrenia therapy was performed with virtual screening on marketed drugs and its metabolites. The identified and available drugs and compounds were further confirmed with in vitro DAAO enzymatic inhibitory assay.